U.S. markets closed
  • S&P Futures

    3,682.75
    -26.25 (-0.71%)
     
  • Dow Futures

    29,492.00
    -177.00 (-0.60%)
     
  • Nasdaq Futures

    11,296.25
    -80.50 (-0.71%)
     
  • Russell 2000 Futures

    1,673.60
    -12.50 (-0.74%)
     
  • Crude Oil

    78.96
    +0.22 (+0.28%)
     
  • Gold

    1,646.70
    -8.90 (-0.54%)
     
  • Silver

    18.62
    -0.29 (-1.53%)
     
  • EUR/USD

    0.9639
    -0.0049 (-0.51%)
     
  • 10-Yr Bond

    3.6970
    -0.0110 (-0.30%)
     
  • Vix

    29.92
    +2.57 (+9.40%)
     
  • GBP/USD

    1.0497
    -0.0359 (-3.31%)
     
  • USD/JPY

    143.7740
    +0.4540 (+0.32%)
     
  • BTC-USD

    18,823.39
    -117.20 (-0.62%)
     
  • CMC Crypto 200

    432.06
    -12.48 (-2.81%)
     
  • FTSE 100

    7,018.60
    -140.92 (-1.97%)
     
  • Nikkei 225

    26,538.97
    -614.86 (-2.26%)
     

CymaBay Therapeutics Inc. (CBAY) Q2 2022 Earnings Call Transcript

·51 min read
CymaBay Therapeutics Inc. (CBAY) Q2 2022 Earnings Call Transcript

Joining me on the call today are Sujal Shah, chief executive officer; Chuck McWherter, chief scientific officer; Dennis Kim, chief medical officer; Lewis Stuart, chief commercial officer; and Dan Menold, VP, finance. Following our prepared remarks, we will open the call for Q&A. Before we begin, I'd like to remind everyone that statements made during this conference call, including the Q&A session relating to CymaBay's expected future performance, business prospects, events or plans, including clinical plans, regulatory approvals, funding and repayment schedules, anticipated time lines and data release date, cash runway and planning for commercialization are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995.